BackC4 Therapeutics Overview

C4 Therapeutics Minority Interest

Track C4 Therapeutics's minority interest ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00

Peer average

Loading

C4 Therapeutics Minority Interest History

Loading

C4 Therapeutics vs. peers: Minority Interest Comparison

Loading

C4 Therapeutics Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

C4 Therapeutics (CCCC) FAQ

As of the most recent data (March 2026), CCCC shows a minority interest of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CCCC's minority interest is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether C4 Therapeutics is outperforming or lagging.

Tracking CCCC's minority interest over time shows whether C4 Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this minority interest page, Stockcircle has C4 Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect minority interest (currently $0) with ownership activity and broader fundamentals.

C4 Therapeutics's minority interest is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.